Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma (ATTAACH)
Pilot Randomized Controlled Trial of Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma (ATTAACH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Farhad Pirouzmand
- Phone Number: 5263 (416) 480-6100
- Email: ATTAACH_Trial@sunnybrook.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years of age
- Any SDH, defined as either acute or encapsulated partially liquefied hematoma in the subdural space diagnosed on a CT scan
- Can have surgical drainage (either burr hole or craniotomy) for aSDH and cSDH
- On therapeutic anticoagulation (DOAC or warfarin) as standard of care therapy prior to presentation for stroke prophylaxis secondary to AF
Exclusion Criteria:
- aSDH requiring decompressive craniectomy
- Mechanical heart valve or moderate to severe mitral stenosis
- Known chronic coagulopathy (elevated INR >1.5 or PTT>40s after anticoagulant reversal, thrombocytopenia with platelet count <50x109/L) that is not amenable to reversal
- >37 days has elapsed since initial diagnosis without recruitment into the trial
- Active gastroduodenal ulcer, urogenital or respiratory tract hemorrhage
- Known pregnancy or breastfeeding
- Indication for therapeutic anticoagulation other than AF
- Pre-randomization brain CT at 2-4 weeks after initial diagnosis or surgery date reveals significant recurrence requiring surgical drainage
- Known to be non-compliant with prior anticoagulant
- MRP decides to restart Warfarin (as opposed to DOACs) as prophylactic anticoagulant as part of standard therapy for the patient after cSDH or aSDH
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Early resumption of anticoagulation
The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 30 +/- 7 after diagnosis of acute or chronic subdural hematoma.
|
Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
|
|
Active Comparator: Delayed resumption of anticoagulation
The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 90 +/- 14 after diagnosis of acute or chronic subdural hematoma.
|
Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment rate
Time Frame: 1 year
|
The number of participants enrolled for each participating institution, measured as the rate of consent for patients meeting eligibility criteria in one year per institution.
Reasons for non-enrollment of eligible patients will be recorded
|
1 year
|
|
Implementation of study protocol
Time Frame: Study completion ~2.5 years
|
The proportion of enrolled participants who have completed follow-up measures at 90 days with complete recording of the functional outcome degree of disability
|
Study completion ~2.5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional outcome - Degree of disability
Time Frame: 90 days
|
Level of disability measured by the modified Rankin Scale (mRS).
The mRS is a core instrument used for measuring the degree of disability or dependence in activities of daily living that is sensitive to thromboembolic and hemorrhagic complications.
It is a clinician-reported measure and widely applied for evaluating stroke patient outcomes.
It is a 7-level ordered categorical scale with scores ranging from 0 (no symptoms/disability) to 6 (death).
The analysis will be categorized as favourable outcome (scores 0-3) versus unfavourable outcome (scores 4-6)
|
90 days
|
|
Functional outcome - Degree of disability
Time Frame: 180 days
|
Level of disability measured by the modified Rankin Scale (mRS).
The mRS is a core instrument used for measuring the degree of disability or dependence in activities of daily living that is sensitive to thromboembolic and hemorrhagic complications.
It is a clinician-reported measure and widely applied for evaluating stroke patient outcomes.
It is a 7-level ordered categorical scale with scores ranging from 0 (no symptoms/disability) to 6 (death).
The analysis will be categorized as favourable outcome (scores 0-3) versus unfavourable outcome (scores 4-6)
|
180 days
|
|
Functional outcome - Stroke-related neurologic deficit
Time Frame: 90 days
|
Measured using the National Institute of Health Stroke Scale (NIHSS) which is a 15-item impairment scale.
It groups scores into categories based on severity, ranging from mild to very severe, with a higher score indicating a greater degree of impairment
|
90 days
|
|
Functional outcome - Stroke-related neurologic deficit
Time Frame: 180 days
|
Measured using the National Institute of Health Stroke Scale (NIHSS) which is a 15-item impairment scale.
It groups scores into categories based on severity, ranging from mild to very severe, with a higher score indicating a greater degree of impairment
|
180 days
|
|
Incidence of intracranial hemorrhage
Time Frame: Continuous, baseline to 180 days
|
The composite outcome of clinically-important intracranial hemorrhage defined by: 1) any increase in volume of blood in the CT of at least 33%; 2) need for surgical evacuation of SDH or repeat surgical evacuation; 3) death directly related to enlarging SDH or new parenchymal bleed; 4) symptomatic bleeding in a critical non-intracranial region
|
Continuous, baseline to 180 days
|
|
Incidence of thromboembolic events
Time Frame: Continuous, baseline to 180 days
|
Composite outcome of clinically-important thromboembolic events defined as any of: 1) symptomatic TIA; 2) symptomatic objectively-confirmed ischemic stroke; 3) symptomatic, objectively-confirmed non-CNS systemic embolism; 4) objectively proven VTE; 5) all death directly or indirectly caused by a thrombotic event
|
Continuous, baseline to 180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Farhad Pirouzmand, MD, MSc, Sunnybrook Health Sciences Centre
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Disease Attributes
- Hemorrhage
- Craniocerebral Trauma
- Trauma, Nervous System
- Arrhythmias, Cardiac
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Chronic Disease
- Atrial Fibrillation
- Hematoma
- Hematoma, Subdural
- Hematoma, Subdural, Chronic
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Factor Xa Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- 3998
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.